Abvc Biopharma Rises On Unit's Tie: up with MerDury BioPharma
06/06/2023 17:54
** Shares of drug developer ABVC BioPharma Inc ABVC.O rise
3% to 63 cents
** Co says its subsidiary BioKey signed an agreement with
MerDury BioPharma to co-develop new drug products using
MerDury's StackDose platform technology
** The platform has the technology to generate new products
with fat release properties when it is administered orally and
performs an automatic 3D printing manufacturing process
** The tech will enable co to develop more IP-protected and
brand-name products for commercialization - ABVC
** Stock down ~1% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner